BTIG Upgrades LENSAR to Buy, Announces $10 Price Target
3/18/2026
Impact: 75
Healthcare
BTIG analyst Ryan Zimmerman has upgraded LENSAR (NASDAQ: LNSR) from a Neutral rating to a Buy rating, setting a price target of $10 for the stock. This upgrade indicates a positive outlook for LENSAR's performance in the market.
AI summary, not financial advice
Share: